Project Grant R43DK109862

This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $298,883 to Iaterion, Inc. to develop a safer menopausal hormone therapy (MHT) formula that can be used long-term to treat protracted menopausal symptoms and prevent chronic diseases like osteoporosis, diabetes, obesity, and metabolic syndrome. The project aims to create an estradiol/reprogramming ligand combination that can potentially replace the progestin component of current MHT...

The National Institute on Aging (NIA) awarded a $391,101 Project Grant under the Aging Research program (CFDA 93.866) to The Ohio State University to develop a novel nonsteroidal and nonhormonal agent that reverses menopause-related loss of genital epithelial integrity and function. The research aims to define the mechanism of action, optimize delivery, and establish the long-term safety profile of an EFNA3-mimetic agonist peptide (EFNA3-MAP) administered intravaginally to restore genital...

The University of Miami was awarded a $447,340 Project Grant by the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) to investigate epigenetic mechanisms and vulnerabilities in endocrine-resistant breast cancer. The 5-year grant, starting on March 1, 2025, aims to identify novel therapeutic targets and improve survival rates for patients with metastatic, endocrine-resistant estrogen receptor positive (ER+) breast cancer. The research will focus on the role of the...

The National Institute of Mental Health (NIMH) awarded a Project Grant under the Mental Health Research Grants program (CFDA 93.242) to Northwestern University for $225,621 from August 2024 to July 2026. The grant, titled "Estrogen and Mechanisms of Psychotic-Like Experiences in the Transition to Adolescence," aims to examine the role of estrogen in the development of psychotic-like experiences during the transition from childhood to adolescence. The project will leverage the rich...

This Project Grant award from the National Institute of Child Health and Human Development (NICHD) under the Child Health and Human Development Extramural Research program (CFDA 93.865) will support research to elucidate the cellular and molecular mechanisms by which uterine epithelial estrogen receptor alpha (ERA) regulates the uterine immune environment during early pregnancy. The $641,750 award to the University of Georgia Research Foundation will fund a 2-year study using a mouse model to...

This $386,855 federal Project Grant awarded by the National Institute of Child Health and Human Development (CFDA 93.865) to King's College London aims to elucidate how follicle-stimulating hormone (FSH) glycoforms modulate the oligomerization and trafficking of the FSH receptor (FSHR) in young and aging ovaries, and the functional consequences thereof. The research will leverage a novel mouse model, high-resolution imaging, and multi-omic approaches to determine how FSHR oligomerization and...

The National Cancer Institute (NCI) awarded a $303,112 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to Virginia Commonwealth University (VCU) on September 30, 2024. The grant supports research to evaluate the efficacy of the FDA-approved drug elacestrant versus standard of care in preclinical models of estrogen receptor-positive (ER+) breast cancer bone metastasis. The project will utilize in vitro, in vivo, and ex vivo models to assess elacestrant's impact on...

This Project Grant award from the National Institute of Child Health and Human Development (NICHD), under the Child Health and Human Development Extramural Research program (CFDA 93.865), is focused on developing a novel, non-hormonal therapeutic for endometriosis. The $2,045,782 award to Endomet Biosciences, Inc., a woman-owned small business, will support activities necessary to commence Phase 1 clinical trials for their ENDO-205 compound. Key objectives include manufacturing GMP clinical drug...

This Project Grant award, totaling $576,926 and awarded by the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242), aims to characterize the cellular and molecular changes in the human anterior hippocampus (a brain region critical for emotion regulation) across the menopausal transition. The research will utilize single-nucleus multiome analysis and micro-C analysis to define the shifts in gene expression, chromatin states, and 3D genome...

This National Cancer Institute project grant of $808,336 provides funding from September 2022 through August 2025 to investigate the effects of androgen receptor antagonism on human T cell function. The University of Portland will determine how androgen deprivation therapies used in prostate cancer treatment impact the adaptive immune response. Researchers will study the impact of the clinically relevant androgen receptor antagonist enzalutamide on T cells isolated from healthy volunteers in...